

Press Release ORGANOBALANCE GmbH, Berlin

ORGANOBALANCE Announces Substantial Investment

Dr Bernd Wegener to invest in Berlin (Germany) Biotech company

Berlin (Germany), 17 June 2010 – ORGANOBALANCE GmbH Berlin and Bernd Wegener, Doctor of Veterinary Medicine (Chairman of the Board of the German Federal Association of the Pharmaceutical Industry), have announced the completion of an investment agreement which shall take immediate effect. Aside from detailing a financial commitment, the agreement also foresees an active role for Dr Wegener in a position of responsibility at ORGANOBALANCE.

Dr Wegener's investment (the extent of which, as agreed between the parties, shall not be disclosed), his extensive experience, expertise and numerous contacts within the pharmaceutical and biotech industries, shall substantially promote and shape the continued successful development of ORGANOBALANCE GmbH.

"We are truly delighted that an expert of Dr. Wegener's immense scientific distinction and experience will join our team at ORGANOBALANCE." Professor Christine Lang, Managing Director of ORGANOBALANCE, commented on the agreed collaboration. "With his support and commitment, we will be able to pursue our strategy of developing new active substances for the pharmaceutical industry much more rapidly and efficiently than previously planned." Professor Lang went on to explain.

Dr Wegener also envisages excellent prospects for their collaboration, commenting that "With innovative, patentable microorganisms and their active principles, we will be able to develop new diagnostic and therapeutic concepts and procedures particularly for hitherto inadequately treatable indications. I am very much looking forward to working with Professor Lang and ORGANOBALANCE, a leading company in this field, and opening up this as yet untapped potential".



About ORGANOBALANCE

ORGANOBALANCE GmbH is a company specialising in strain development and microbiological screening. ORGANOBALANCE taps the potential of beneficial microorganisms, known as specific probiotic cultures, in order to counteract, in a natural way, imbalances in the microflora, thus restoring the microbial equilibrium. In close cooperation with renowned industry partners, ORGANOBALANCE develops new biological products in the fields of pharmaceutics, preventive health care, nutrition and cosmetics. In its development activities the company draws on its own collection of microorganisms suitable for use in foodstuffs as well as its own OASSYS® screening systems. ORGANOBALANCE was founded in 2001 and is based in Berlin (Germany). More information can be found at www.organobalance.com.

About Dr Wegener:

Bernd Wegener, DVM, has extensive managerial experience from diverse areas of responsibility in the pharmaceutical industry and relevant associations. After holding positions at Boehringer Ingelheim KG, Degussa Pharmagruppe, Marion Merrell Dow GmbH and Henning Berlin GmbH, he was Chairman of the Board of the B•R•A•H•M•S Group from 1994 to May 2010.

Dr Wegener is also Chairman of the Board of the German Federal Association of the Pharmaceutical Industry as well as being a member of the board of various associations and supervisory boards.

All product and company names mentioned herein are possibly protected, and the property of ORGANOBALANCE GmbH or other companies.



For further please contact:

ORGANOBALANCE GmbH Mrs Kristin Ebert Gustav-Meyer-Allee 25 13355 Berlin

Tel.: +49 30 46307-200 Fax: +49 30 46307-210

Email: info@organobalance.com

Internet: http://www.organobalance.com

1779 characters

Approved for publication. Specimen copy kindly requested.